Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring.
Végvári, Ákos LU ; Sjödin, Karin LU ; Rezeli, Melinda LU
; Malm, Johan
LU
; Lilja, Hans
LU
; Laurell, Thomas
LU
and Marko-Varga, György
LU
(2013)
In Molecular & Cellular Proteomics
12(10).
p.2761-2773
- Abstract
- Prostate specific antigen (PSA) is a well-established tumor marker, which is frequently employed as model biomarker to develop and evaluate emerging quantitative proteomics techniques, partially due to wide access to commercialized immunoassays serving as "gold standard". We designed a multiple reaction monitoring (MRM) assay to detect PSA proteoforms in clinical samples (n=72), utilizing specificity and sensitivity of the method. We report for the first time, a PSA proteoform, coded by SNP-L132I (rs2003783), observed in 9 samples in both heterozygous (n=7) and homozygous (n=2) expression profiles. Other isoforms of PSA, derived from protein databases, were not identified by four unique proteotypic tryptic peptides. We have also utilized... (More)
- Prostate specific antigen (PSA) is a well-established tumor marker, which is frequently employed as model biomarker to develop and evaluate emerging quantitative proteomics techniques, partially due to wide access to commercialized immunoassays serving as "gold standard". We designed a multiple reaction monitoring (MRM) assay to detect PSA proteoforms in clinical samples (n=72), utilizing specificity and sensitivity of the method. We report for the first time, a PSA proteoform, coded by SNP-L132I (rs2003783), observed in 9 samples in both heterozygous (n=7) and homozygous (n=2) expression profiles. Other isoforms of PSA, derived from protein databases, were not identified by four unique proteotypic tryptic peptides. We have also utilized our MRM assay for precise quantitative analysis of PSA concentrations in both seminal and blood plasma samples. The analytical performance was evaluated, providing close agreement between each quantitation based on three selected peptides (LSEPAELTDAVK, IVGGWECEK and SVILLGR) and a routinely used commercialized immunoassay. Additionally, we have disclosed that the peptide IVGGWECEK is shared with kallikrein-related peptidase 2 and therefore not unique for PSA. Hence, we propose to use another tryptic sequence (SVILLGR) for accurate MRM-quantification of PSA in clinical samples. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3955991
- author
- Végvári, Ákos
LU
; Sjödin, Karin
LU
; Rezeli, Melinda
LU
; Malm, Johan
LU
; Lilja, Hans
LU
; Laurell, Thomas
LU
and Marko-Varga, György
LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Molecular & Cellular Proteomics
- volume
- 12
- issue
- 10
- pages
- 2761 - 2773
- publisher
- American Society for Biochemistry and Molecular Biology
- external identifiers
-
- pmid:23842001
- wos:000330537000008
- scopus:84885092136
- pmid:23842001
- ISSN
- 1535-9484
- DOI
- 10.1074/mcp.M113.028365
- language
- English
- LU publication?
- yes
- id
- e5abc9b9-890d-4288-bca3-1bc2f5b8917d (old id 3955991)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23842001?dopt=Abstract
- date added to LUP
- 2016-04-01 10:16:36
- date last changed
- 2023-08-30 22:32:46
@article{e5abc9b9-890d-4288-bca3-1bc2f5b8917d,
abstract = {{Prostate specific antigen (PSA) is a well-established tumor marker, which is frequently employed as model biomarker to develop and evaluate emerging quantitative proteomics techniques, partially due to wide access to commercialized immunoassays serving as "gold standard". We designed a multiple reaction monitoring (MRM) assay to detect PSA proteoforms in clinical samples (n=72), utilizing specificity and sensitivity of the method. We report for the first time, a PSA proteoform, coded by SNP-L132I (rs2003783), observed in 9 samples in both heterozygous (n=7) and homozygous (n=2) expression profiles. Other isoforms of PSA, derived from protein databases, were not identified by four unique proteotypic tryptic peptides. We have also utilized our MRM assay for precise quantitative analysis of PSA concentrations in both seminal and blood plasma samples. The analytical performance was evaluated, providing close agreement between each quantitation based on three selected peptides (LSEPAELTDAVK, IVGGWECEK and SVILLGR) and a routinely used commercialized immunoassay. Additionally, we have disclosed that the peptide IVGGWECEK is shared with kallikrein-related peptidase 2 and therefore not unique for PSA. Hence, we propose to use another tryptic sequence (SVILLGR) for accurate MRM-quantification of PSA in clinical samples.}},
author = {{Végvári, Ákos and Sjödin, Karin and Rezeli, Melinda and Malm, Johan and Lilja, Hans and Laurell, Thomas and Marko-Varga, György}},
issn = {{1535-9484}},
language = {{eng}},
number = {{10}},
pages = {{2761--2773}},
publisher = {{American Society for Biochemistry and Molecular Biology}},
series = {{Molecular & Cellular Proteomics}},
title = {{Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring.}},
url = {{https://lup.lub.lu.se/search/files/1708171/4173777.pdf}},
doi = {{10.1074/mcp.M113.028365}},
volume = {{12}},
year = {{2013}},
}